Key result
Cannabidiol reduces cardiac fibrosis and diastolic dysfunction in HFpEF by clearing senescent cells.
Why the study?
Heart failure with preserved ejection fraction (HFpEF) lacks effective therapies and the cardioprotective efficacy and mechanisms of cannabidiol (CBD) in HFpEF are poorly understood.
Does Cannabidiol (CBD) improve diastolic dysfunction, cellular senescence, and inflammation in a murine model of HFpEF?
Does Cannabidiol (CBD) improve diastolic dysfunction, cellular senescence, and inflammation in a murine model of HFpEF?
In a murine HFpEF model, CBD mitigated diastolic dysfunction and cardiac fibrosis by modulating cellular senescence and NLRP3-mediated inflammation through preservation of Mitochondria-Endoplasmic Reticulum Contact Sites (MERCSs).
Heart failure with preserved ejection fraction (HFpEF) remains a clinical challenge lacking effective therapies. While Cannabidiol (CBD) suggests cardioprotective potential, its efficacy and underlying in HFpEF are poorly understood. This study investigated the effects of CBD on a murine model of HFpEF induced by a high-fat diet and L-NAME for 8 weeks. CBD was administered subcutaneously every three days. Hemodynamic performance was assessed via invasive pressure-volume loops, complemented by histological analysis and oxidative stress markers. Cellular senescence, NLRP3-mediated inflammation and Mitochondria-Endoplasmic Reticulum Contact Sites (MERCSs) were evaluated through immunofluorescence, RT-qPCR, and transmission electron microscopy. CBD treatment failed to reduce cardiac hypertrophy but improves cardiac fibrosis and diastolic dysfunction. These improvements were associated with a marked reduction in senescent cells accumulation and on systemic cytokine levels that may be associated with the senescence-associated secretory phenotype (SASP). Notably, CBD suppressed the NLR3-mediated proinflammatory state by preserving inter-organelle distance and MERCSs integrity. Our findings demonstrate, for the first time, that CBD modulates MERCSs communication to regulate senescence and inflammation in HFpEF. These results position CBD as a promising intervention for mitigating the pathology of HFpEF through the regulation of MERCSs, although the signaling pathways involved in this protective mechanism need to be characterized.
No takes yet. Share an insight, caveat, or question.
Silva‐Palacios et al. (2026) studied Heart failure with preserved ejection fraction (HFpEF). Cannabidiol (CBD) was evaluated on Cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cannabidiol administration improved cardiac fibrosis and diastolic dysfunction in a murine HFpEF model by reducing senescent cell accumulation and preserving MERCSs integrity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: